This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: 23Andme, Inc.. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: Lindsay Deis: Innovator in Asthma Treatment
Introduction
Lindsay Deis is a notable inventor based in San Bruno, CA (US). He has made significant contributions to the field of medical research, particularly in the treatment of asthma. With a focus on innovative solutions, Deis has been awarded 2 patents for his groundbreaking work.
Latest Patents
Deis's latest patents include a method of treating asthma with anti-IL1RAP antibodies. This invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP). These proteins fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Additionally, the patents cover compositions comprising such binding proteins and methods of making and using them.
Career Highlights
Lindsay Deis is currently employed at 23andMe, Inc., where he continues to innovate in the field of biotechnology. His work focuses on developing new therapeutic approaches to improve patient outcomes in asthma treatment.
Collaborations
Deis collaborates with talented individuals such as Erik E. Karrer and Germaine Fuh-Kelly, contributing to a dynamic research environment that fosters innovation.
Conclusion
Lindsay Deis is a prominent inventor whose work in asthma treatment showcases his commitment to advancing medical science. His patents reflect a deep understanding of the complexities of immune signaling and offer promising avenues for future research and development.